---
title: Parasympathetic Drugs - Cholinergic Pharmacology
type: content
phase: 1
status: complete
priority: high
tags: [parasympathetic, cholinergic, muscarinic, nicotinic, acetylcholine, cholinesterase-inhibitors, anticholinergics]
created: 2025-11-08
last_modified: 2025-11-08
---

# Parasympathetic Drugs - Cholinergic Pharmacology

## Introduction

Parasympathetic drugs affect the cholinergic system by acting on cholinergic receptors or modulating acetylcholine neurotransmission. These drugs are essential in treating conditions affecting the gastrointestinal, urinary, respiratory, cardiovascular, and nervous systems.

## Cholinergic System Review

### Acetylcholine (ACh) Synthesis and Metabolism

**Synthesis**:
```
Choline + Acetyl-CoA → [Choline Acetyltransferase] → Acetylcholine
```

**Degradation**:
```
Acetylcholine → [Acetylcholinesterase] → Choline + Acetate
```

**Acetylcholinesterase (AChE)**:
- Located at synapses (neuromuscular junction, ganglia, muscarinic sites)
- Rapid hydrolysis (microseconds)
- Essential for terminating ACh action

**Butyrylcholinesterase (Pseudocholinesterase)**:
- Plasma enzyme
- Broader substrate specificity
- Slower than AChE
- Clinical relevance: Succinylcholine metabolism, cocaine metabolism

### Cholinergic Receptors

#### Nicotinic Receptors (Ionotropic)

**Structure**: Pentameric ligand-gated ion channels (Na+/K+)

**Types**:
1. **Nn (Neuronal/Ganglionic)**:
   - Location: Autonomic ganglia, adrenal medulla, CNS
   - Composition: α3β4 primarily
   - Blockers: Hexamethonium, mecamylamine, trimethaphan

2. **Nm (Muscle)**:
   - Location: Neuromuscular junction (skeletal muscle)
   - Composition: (α1)2β1δε (adult), (α1)2β1δγ (fetal)
   - Blockers: Neuromuscular blockers (see separate file)

**Mechanism**: ACh binding → channel opening → Na+ influx, K+ efflux → depolarization

#### Muscarinic Receptors (Metabotropic/GPCRs)

**M1** (Gq → ↑IP3/DAG → ↑Ca2+):
- Location: Gastric parietal cells, CNS (cortex, hippocampus), autonomic ganglia
- Effects: ↑Gastric acid secretion, cognitive function, ganglionic excitation

**M2** (Gi → ↓cAMP, ↑K+ conductance):
- Location: Heart (SA node, atria, AV node, ventricles)
- Effects: ↓HR (negative chronotropy), ↓conduction velocity (negative dromotropy), ↓contractility (negative inotropy - atria > ventricles)

**M3** (Gq → ↑IP3/DAG → ↑Ca2+):
- Location: Smooth muscle (GI, bladder, bronchi, iris, ciliary), glands (salivary, lacrimal, sweat), vascular endothelium
- Effects: ↑GI motility, bladder contraction, bronchoconstriction, miosis, accommodation, glandular secretion, vasodilation (via NO from endothelium)

**M4** (Gi):
- Location: CNS
- Effects: Modulation of neurotransmitter release

**M5** (Gq):
- Location: CNS, vascular smooth muscle
- Effects: Vasodilation

**Mnemonic**: 
- **Odd receptors (M1, M3, M5)**: Gq
- **Even receptors (M2, M4)**: Gi

### Cholinergic Effects by Organ System

**Cardiovascular**:
- ↓HR, ↓AV conduction (M2)
- Vasodilation (M3 → endothelial NO)

**Respiratory**:
- Bronchoconstriction (M3)
- ↑Secretions

**Gastrointestinal**:
- ↑Motility, ↑secretions (M3)
- ↑Gastric acid (M1)
- Relaxation of sphincters

**Urinary**:
- Detrusor contraction (M3)
- Sphincter relaxation
- Promotes urination

**Eye**:
- Miosis - pupil constriction (M3, iris sphincter)
- Accommodation - near vision (M3, ciliary muscle)
- ↓Intraocular pressure (IOP)

**Glands**:
- ↑Secretions: Salivary, lacrimal, bronchial, sweat (M3)

**CNS**:
- Memory, learning (M1)
- Motor control

---

## Cholinomimetics (Parasympathomimetics)

### Classification

1. **Direct-acting**: Bind and activate cholinergic receptors
   - Muscarinic agonists
   - Nicotinic agonists
2. **Indirect-acting**: Inhibit acetylcholinesterase → ↑ACh
   - Reversible
   - Irreversible

---

## Direct-Acting Cholinomimetics

### Choline Esters

**Acetylcholine**:

**Receptor Activity**: Non-selective (muscarinic and nicotinic)

**Pharmacokinetics**:
- Rapidly hydrolyzed by AChE and butyrylcholinesterase
- Not orally active (charged, rapidly metabolized)
- No clinical use systemically
- Duration: Seconds

**Clinical Use**: Research only; ophthalmic (intraocular - miosis during surgery)

**Bethanechol**:

**Structure**: Carbamyl ester (resistant to cholinesterases)

**Receptor Activity**: Selective muscarinic (M3 > M2)

**Pharmacokinetics**:
- Oral, SC (NOT IV/IM - severe cholinergic crisis)
- Resistant to cholinesterases
- Duration: 1 hour (SC), 6 hours (oral)
- Poor lipid solubility (quaternary amine) - doesn't cross BBB

**Pharmacodynamics**:
- ↑GI motility, ↑GI secretions
- ↑Bladder contraction, ↓bladder sphincter tone
- Minimal cardiovascular effects (M3 > M2)
- Minimal nicotinic effects

**Clinical Uses**:
1. **Postoperative urinary retention**
2. **Neurogenic bladder** (atonic bladder)
3. **Postoperative ileus** (rarely used)
4. **GERD** (rarely used - metoclopramide preferred)

**Adverse Effects**:
- Abdominal cramps, diarrhea
- Urinary urgency
- Excessive salivation
- Sweating
- Bradycardia (if reaches M2 receptors)

**Contraindications**:
- Mechanical obstruction (GI or urinary)
- Active peptic ulcer
- Asthma (bronchoconstriction risk)
- Hyperthyroidism
- Coronary artery disease
- Recent GI/bladder surgery

**Antidote**: Atropine (muscarinic antagonist)

**Carbachol**:

**Receptor Activity**: Muscarinic and nicotinic (non-selective)

**Clinical Use**: **Glaucoma** (topical ophthalmic)
- Miosis → ↑trabecular outflow → ↓IOP

**Not used systemically**: Too many side effects (nicotinic + muscarinic)

**Methacholine**:

**Receptor Activity**: Selective muscarinic

**Pharmacodynamics**: Bronchoconstriction (M3)

**Clinical Use**: **Bronchial challenge test** for asthma diagnosis
- Detects airway hyperreactivity
- Positive test: >20% ↓FEV1

**Not used therapeutically**: Pure diagnostic

---

### Alkaloids

**Pilocarpine**:

**Source**: Pilocarpus plant

**Structure**: Tertiary amine (lipophilic)

**Receptor Activity**: Selective muscarinic

**Pharmacokinetics**:
- Oral, topical (ophthalmic)
- Crosses BBB (tertiary amine)

**Pharmacodynamics**:
- Potent miosis
- ↓IOP (↑trabecular outflow + ↓aqueous humor production)
- Accommodation spasm
- ↑Secretions (salivary, sweat)

**Clinical Uses**:
1. **Glaucoma** (topical ophthalmic) - open-angle and angle-closure
   - First-line: Latanoprost (prostaglandin); pilocarpine second-line
2. **Xerostomia** (dry mouth) - especially post-radiation or Sjögren syndrome
   - Oral tablets: 5-10 mg TID

**Adverse Effects**:
- Blurred vision (accommodation spasm)
- Headache (ciliary muscle spasm)
- Sweating, salivation
- Bradycardia
- Bronchospasm (caution in asthma)

**Contraindications**: Angle-closure glaucoma (if iritis present), asthma

**Muscarine**:
- Toxin from Amanita muscaria mushrooms
- Prototype muscarinic agonist (research)
- No clinical use
- Toxicity: SLUDGE symptoms (see below)

**Arecoline**:
- Alkaloid in betel nut
- Muscarinic and nicotinic agonist
- No clinical use
- Cultural use: Betel quid chewing (carcinogenic)

---

## Indirect-Acting Cholinomimetics (Anticholinesterases)

### Mechanism of Action

Inhibit acetylcholinesterase → ↑ACh at all cholinergic synapses (muscarinic and nicotinic)

**Effects**:
- Muscarinic: SLUDGE symptoms
- Nicotinic (Nm): Muscle fasciculations → paralysis (high doses)
- Nicotinic (Nn): Ganglionic stimulation → hypertension, then hypotension

### Reversible Anticholinesterases

**Edrophonium**:

**Mechanism**: Competitive, reversible AChE inhibitor

**Pharmacokinetics**:
- IV only
- Ultra-short duration (5-10 minutes)
- Rapid onset (30-60 seconds)

**Clinical Uses**:
1. **Diagnosis of myasthenia gravis** (Tensilon test)
   - Give IV edrophonium
   - Positive: Rapid improvement in muscle strength
   - Negative: No improvement or worsening (cholinergic crisis)
2. **Differentiate myasthenic crisis from cholinergic crisis**
   - Myasthenic: Improves with edrophonium
   - Cholinergic: Worsens with edrophonium
3. **Reversal of neuromuscular blockade** (rarely - neostigmine preferred)

**Adverse Effects**: Cholinergic (brief due to short duration)

**Note**: Largely replaced by antibody testing (anti-AChR, anti-MuSK) for MG diagnosis

**Neostigmine**:

**Mechanism**: Carbamyl ester, reversible AChE inhibitor (covalent but reversible)

**Pharmacokinetics**:
- Oral, IM, IV
- Quaternary amine (poorly absorbed orally, doesn't cross BBB)
- Duration: 2-4 hours

**Pharmacodynamics**:
- ↑ACh at all cholinergic sites
- Muscarinic and nicotinic effects

**Clinical Uses**:
1. **Reversal of non-depolarizing neuromuscular blockade**
   - Given with atropine or glycopyrrolate to prevent muscarinic effects
   - Dose: 0.04-0.08 mg/kg IV
2. **Myasthenia gravis** (oral)
   - Less commonly used (pyridostigmine preferred)
3. **Postoperative urinary retention, ileus**

**Adverse Effects**:
- **Muscarinic**: SLUDGE (salivation, lacrimation, urination, defecation, GI upset, emesis)
- **Nicotinic**: Muscle fasciculations, weakness (high doses)
- Bradycardia, AV block
- Bronchoconstriction

**Antidote**: Atropine (for muscarinic effects)

**Pyridostigmine**:

**Mechanism**: Reversible AChE inhibitor (like neostigmine)

**Pharmacokinetics**:
- Oral, IV
- Longer duration than neostigmine (3-6 hours)
- Quaternary amine

**Clinical Uses**:
1. **Myasthenia gravis** (drug of choice for chronic therapy)
   - Oral: 30-120 mg q4-6h
   - Improves muscle strength
2. **Reversal of neuromuscular blockade** (alternative to neostigmine)
3. **Prophylaxis for nerve agent exposure** (military)

**Advantages over neostigmine**: Longer duration, smoother action, fewer GI side effects

**Adverse Effects**: Similar to neostigmine (cholinergic)

**Physostigmine**:

**Mechanism**: Carbamyl ester, reversible AChE inhibitor

**Pharmacokinetics**:
- Oral, IM, IV, topical
- **Tertiary amine** (crosses BBB and blood-eye barrier)
- Duration: 30 minutes - 2 hours

**Pharmacodynamics**: 
- Central and peripheral cholinergic effects

**Clinical Uses**:
1. **Anticholinergic toxicity** (atropine, antihistamines, TCAs)
   - Reverses central anticholinergic syndrome
   - Crosses BBB (unlike neostigmine)
2. **Glaucoma** (topical) - rarely used now

**Adverse Effects**: Cholinergic (including CNS: seizures at high doses)

**Contraindications**: Asthma, GI/GU obstruction, cardiovascular disease

**Donepezil, Rivastigmine, Galantamine**:

**Mechanism**: Reversible AChE inhibitors

**Pharmacokinetics**:
- Oral
- Cross BBB (lipophilic)
- Donepezil: Long half-life (70h), QD dosing
- Rivastigmine: Shorter half-life, BID dosing; also available as patch
- Galantamine: BID dosing

**Additional Mechanism**:
- Galantamine: Also allosteric modulator of nicotinic receptors

**Clinical Use**: **Alzheimer disease**
- Mild to moderate Alzheimer disease
- Enhance cholinergic neurotransmission in CNS
- Modest symptomatic benefit (↑cognition, ↓decline)
- Do NOT alter disease progression

**Adverse Effects**:
- **GI**: Nausea, vomiting, diarrhea (most common, dose-related)
- Anorexia, weight loss
- Bradycardia, syncope
- Insomnia, vivid dreams
- Muscle cramps

**Contraindications**: Sick sinus syndrome, bradycardia

**Monitoring**: ECG if cardiac disease

### Irreversible Anticholinesterases

**Organophosphates**:

**Examples**:
- **Insecticides**: Parathion, malathion, diazinon
- **Nerve agents**: Sarin, soman, tabun, VX

**Mechanism**: 
- Covalent phosphorylation of AChE serine residue
- **Irreversible** (unless treated early with pralidoxime)
- "Aging": Over time (hours), phosphorylated enzyme becomes resistant to reactivation

**Pharmacokinetics**:
- Highly lipophilic
- Absorbed via skin, lungs, GI tract
- Accumulate in fat
- Some require metabolic activation (parathion → paraoxon)

**Toxicity**:

**Acute Cholinergic Crisis** (minutes to hours):

**Muscarinic Effects** (SLUDGE):
- **S**: Salivation
- **L**: Lacrimation
- **U**: Urination
- **D**: Defecation
- **G**: GI upset (cramps, nausea, vomiting)
- **E**: Emesis
- **Plus**: Miosis, bronchospasm, bronchorrhea, bradycardia, sweating

**Mnemonic**: DUMBELS
- **D**: Defecation, Diaphoresis
- **U**: Urination
- **M**: Miosis
- **B**: Bronchospasm, Bronchorrhea, Bradycardia
- **E**: Emesis
- **L**: Lacrimation
- **S**: Salivation

**Nicotinic Effects**:
- Muscle fasciculations → weakness → paralysis (including respiratory muscles)
- Hypertension, tachycardia (ganglionic stimulation initially)

**CNS Effects**:
- Anxiety, confusion, seizures, coma
- Respiratory depression

**Treatment**:

1. **Decontamination**: Remove clothing, wash skin

2. **Atropine** (competitive muscarinic antagonist):
   - Reverses muscarinic effects (SLUDGE, bronchospasm)
   - Does NOT reverse nicotinic effects (paralysis)
   - Dose: 2-5 mg IV, repeat q5-10min until "atropinization" (dry mouth, mydriasis, HR >80)
   - Large doses may be needed (hundreds of mg)

3. **Pralidoxime (2-PAM)** (cholinesterase reactivator):
   - Breaks organophosphate-AChE bond (if not "aged")
   - Reverses nicotinic effects (muscle weakness)
   - Dose: 1-2 g IV over 15-30 min, then infusion
   - Must give early (within hours, before aging)

4. **Benzodiazepines**: For seizures (diazepam or lorazepam)

5. **Supportive care**: Airway management, ventilation, fluids

**Intermediate Syndrome** (24-96h after exposure):
- Weakness of proximal muscles, neck, respiratory muscles
- Mechanism unclear (possibly nicotinic receptor dysfunction)
- Requires ventilatory support

**Organophosphate-Induced Delayed Polyneuropathy (OPIDP)** (1-3 weeks):
- "Dying-back" axonal degeneration
- Weakness, paresthesias
- May be permanent
- Mechanism: Inhibition of neuropathy target esterase (NTE)

**Echothiophate**:
- Irreversible AChE inhibitor
- **Ophthalmic use** for glaucoma (rarely used)
- Long duration (days)

---

## Anticholinergics (Muscarinic Antagonists)

### Mechanism

Competitive antagonists at muscarinic receptors (M1-M5)

### Atropine and Related Alkaloids

**Atropine**:

**Source**: Atropa belladonna (deadly nightshade), Datura stramonium

**Receptor Activity**: Non-selective muscarinic antagonist (M1-M5)

**Pharmacokinetics**:
- Oral, IM, IV, topical (ophthalmic)
- Tertiary amine → crosses BBB
- Half-life: 2-4 hours
- Hepatic metabolism, renal excretion

**Pharmacodynamics** (dose-dependent):

**Low doses (0.5 mg)**:
- ↓Salivation, sweating (M3)
- Bradycardia (paradoxical - blocks M1 on SA node vagal ganglia)

**Moderate doses (1 mg)**:
- Mydriasis, cycloplegia (M3 on iris, ciliary)
- Tachycardia (M2 blockade)
- Dry mouth

**Higher doses (2-5 mg)**:
- ↓GI motility (M3)
- ↓Bladder contraction (M3)
- Bronchodilation (M3)
- CNS stimulation

**Toxic doses (>10 mg)**:
- Hallucinations, delirium, hyperthermia, seizures, coma

**Clinical Uses**:

1. **Bradycardia** (especially with hypotension)
   - Dose: 0.5-1 mg IV, repeat q3-5min (max 3 mg)
   - Vagal-mediated bradycardia

2. **Organophosphate/carbamate poisoning**
   - Reverses muscarinic effects
   - Dose: 2-5 mg IV, repeat until atropinization
   - May require very large doses

3. **Preanesthetic medication** (antisialagogue)
   - Reduces secretions
   - Less commonly used now

4. **Ophthalmic** (mydriasis, cycloplegia)
   - Pupil dilation for examination
   - Cycloplegia for refraction

5. **Antispasmodic** (GI, bladder spasms)
   - Limited use (other agents preferred)

**Adverse Effects** ("anticholinergic effects"):
- **Peripheral**:
  - Dry mouth (xerostomia)
  - Blurred vision (cycloplegia)
  - Photophobia (mydriasis)
  - Urinary retention
  - Constipation
  - Tachycardia
  - Hyperthermia (↓sweating)
  
- **Central** (crosses BBB):
  - Confusion, delirium
  - Hallucinations
  - Agitation
  - Amnesia

**Anticholinergic Toxicity** ("anticholinergic syndrome"):

**Mnemonic**: 
- "**Blind as a bat**" (mydriasis, cycloplegia)
- "**Dry as a bone**" (↓secretions, sweating)
- "**Red as a beet**" (vasodilation, hyperthermia)
- "**Hot as a hare**" (hyperthermia)
- "**Mad as a hatter**" (delirium, hallucinations)

**Treatment**:
- Supportive care
- **Physostigmine** 1-2 mg IV slowly (if severe CNS symptoms)
  - Reverses central anticholinergic syndrome
  - Caution: Risk of cholinergic crisis, seizures

**Contraindications**:
- Angle-closure glaucoma (acute attack)
- Prostatic hyperplasia (urinary retention risk)
- Paralytic ileus
- Myasthenia gravis (worsens weakness)
- Tachyarrhythmias

**Scopolamine (Hyoscine)**:

**Similar to atropine** but:
- **More potent** at preventing motion sickness
- **More CNS effects** (sedation, amnesia)
- **Less tachycardia**

**Clinical Uses**:
1. **Motion sickness** (most effective agent)
   - Transdermal patch (behind ear)
   - Apply 4h before travel
2. **Postoperative nausea/vomiting**
3. **Antisialagogue**

**Adverse Effects**: Similar to atropine; more sedation

**Homatropine, Tropicamide, Cyclopentolate**:

**Use**: **Ophthalmic** (mydriasis, cycloplegia)

**Characteristics**:
- Shorter duration than atropine
- Preferred for eye exams
- Tropicamide: Shortest (6h), preferred for routine exam
- Cyclopentolate: Intermediate
- Homatropine: Longer

---

### Synthetic Anticholinergics

**Ipratropium, Tiotropium**:

**Receptor Activity**: Non-selective muscarinic antagonists

**Pharmacokinetics**:
- **Inhalation only** (quaternary amines - poorly absorbed systemically)
- Minimal systemic effects
- Tiotropium: Longer duration (24h) vs. ipratropium (6h)

**Mechanism**: Bronchodilation (block M3 on airway smooth muscle)

**Clinical Uses**:

1. **COPD** (first-line maintenance)
   - Ipratropium: QID dosing
   - Tiotropium: QD dosing (preferred)
   - Superior to β-agonists in COPD

2. **Asthma** (adjunct)
   - Combined with β-agonists (Combivent = ipratropium + albuterol)
   - Not first-line (β-agonists preferred)

**Advantages**:
- Minimal systemic absorption
- Fewer side effects than atropine
- No tachyphylaxis

**Adverse Effects**:
- Dry mouth (most common)
- Bitter taste
- Urinary retention (rare)
- Angle-closure glaucoma (rare, if sprayed in eye)

**Glycopyrrolate**:

**Receptor Activity**: Non-selective muscarinic antagonist

**Pharmacokinetics**:
- IV, IM, oral
- Quaternary amine (doesn't cross BBB or placenta)
- Longer duration than atropine

**Clinical Uses**:
1. **Reversal of neuromuscular blockade** (with neostigmine)
   - Prevents bradycardia, excessive secretions from neostigmine
2. **Bradycardia** (alternative to atropine)
3. **Antisialagogue** (reduce secretions)
4. **Peptic ulcer disease** (rarely used)

**Advantages over atropine**:
- No CNS effects (quaternary)
- Less tachycardia
- Longer duration

**Oxybutynin, Tolterodine, Solifenacin, Darifenacin**:

**Receptor Activity**: 
- Oxybutynin, tolterodine, solifenacin: Non-selective muscarinic
- Darifenacin: M3-selective

**Clinical Use**: **Overactive bladder (OAB)**
- ↓Detrusor muscle contractions (M3)
- ↓Urgency, frequency, urge incontinence

**Pharmacokinetics**:
- Oral
- Oxybutynin: Also transdermal patch, gel
- Darifenacin: More selective → fewer side effects theoretically

**Adverse Effects**:
- Dry mouth (most common, dose-limiting)
- Constipation
- Blurred vision
- Urinary retention (paradoxical if outlet obstruction)
- Cognitive impairment (especially elderly - tertiary amines cross BBB)

**Contraindications**: Urinary retention, gastric retention, uncontrolled angle-closure glaucoma

**Trospium, Fesoterodine**: Newer agents for OAB

**Benztropine, Trihexyphenidyl**:

**Receptor Activity**: Muscarinic antagonists with anticholinergic effects

**Clinical Uses**:
1. **Parkinson disease** (adjunct)
   - Reduces tremor more than bradykinesia
   - Less effective than levodopa
2. **Drug-induced parkinsonism** (antipsychotics)
3. **Acute dystonia** (antipsychotic side effect)

**Mechanism**: 
- Restore balance between dopamine and ACh in striatum
- Parkinson: ↓dopamine → relative ↑ACh → tremor
- Anticholinergics ↓ACh effects

**Adverse Effects**: Anticholinergic (confusion especially in elderly)

**Dicyclomine, Hyoscyamine**:

**Clinical Use**: **Irritable bowel syndrome (IBS)**, GI spasms
- Antispasmodic effects
- Limited efficacy

**Adverse Effects**: Anticholinergic

---

### Ganglionic Blockers

**Mechanism**: Nicotinic (Nn) receptor antagonists at autonomic ganglia

**Drugs**:
- **Mecamylamine**: Oral
- **Trimethaphan**: IV (discontinued in US)
- **Hexamethonium**: Historical (research)

**Effects**:
- Block both sympathetic and parasympathetic ganglia
- Sympathetic generally predominates in most organs

**Clinical Use** (historical):
- Severe hypertension (rarely used now - many side effects)

**Adverse Effects**:
- Orthostatic hypotension (loss of reflex sympathetic compensation)
- Sexual dysfunction
- Constipation, ileus
- Blurred vision
- Urinary retention

**Largely abandoned** due to poor tolerability and better alternatives

---

## Clinical Pearls

1. **SLUDGE for muscarinic agonist effects**: Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis
2. **DUMBELS for organophosphate poisoning**: Add Diaphoresis, Miosis, Bronchospasm, Bronchorrhea, Bradycardia
3. **Anticholinergic toxicity mnemonic**: Blind as bat, Dry as bone, Red as beet, Hot as hare, Mad as hatter
4. **Atropine for organophosphate poisoning**: Reverses muscarinic effects only
5. **Pralidoxime for organophosphate poisoning**: Reverses nicotinic effects (muscle weakness); must give early
6. **Edrophonium test for myasthenia gravis**: Rapid improvement if MG; largely replaced by antibody testing
7. **Pyridostigmine for myasthenia gravis**: Drug of choice for chronic therapy
8. **Cholinesterase inhibitors for Alzheimer disease**: Donepezil most commonly used (QD dosing)
9. **Ipratropium/tiotropium for COPD**: First-line maintenance; minimal systemic effects
10. **Anticholinergics for overactive bladder**: Dry mouth is dose-limiting side effect
11. **Physostigmine crosses BBB**: Reverses central anticholinergic syndrome
12. **Bethanechol for urinary retention**: Never give IV (severe cholinergic crisis)
13. **Scopolamine patch for motion sickness**: Most effective agent
14. **Avoid anticholinergics in elderly**: Delirium, cognitive impairment (Beers Criteria)

---

## Key Takeaways

1. **Cholinergic receptors**: Muscarinic (M1-M5, GPCRs) and Nicotinic (Nn, Nm, ionotropic)
2. **Direct cholinomimetics**: Bethanechol (urinary retention), pilocarpine (glaucoma, xerostomia)
3. **Anticholinesterases**: ↑ACh by inhibiting AChE
4. **Reversible anticholinesterases**: Neostigmine (reverse NMB), pyridostigmine (MG), donepezil (Alzheimer)
5. **Organophosphate poisoning**: Atropine (muscarinic) + pralidoxime (nicotinic) + supportive care
6. **Atropine**: Bradycardia, organophosphate poisoning, antisialagogue; anticholinergic side effects
7. **Anticholinergic toxicity**: Blind, dry, red, hot, mad; treat with physostigmine if severe CNS symptoms
8. **Ipratropium/tiotropium**: Inhaled anticholinergics for COPD (first-line)
9. **Oxybutynin, tolterodine**: Overactive bladder; dry mouth common
10. **Myasthenia gravis**: Pyridostigmine first-line; edrophonium for diagnosis (historical)

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. Rang & Dale's Pharmacology, 9th Edition
4. GOLD Guidelines for COPD Management
5. AUA/SUFU Guidelines for Overactive Bladder
